Lower incidence of COVID-19 in patients with inflammatory bowel disease treated with non-gut selective biologic therapy.

Sandro ArdizzoneFrancesca FerrettiMaria Camilla MonicoAnna Maria Carvalhas GabrielliStefania CarmagnolaCristina BezzioSimone SaibeniMatteo BosaniFlavio CaprioliStefano MazzaValentina CasiniClaudio Camillo CortelezziMarco ParraviciniAndrea CassinottiPaola CosimoAmedeo IndrioloAntonio Di SabatinoMarco Vincenzo LentiLuca PastorelliFrancesco ConfortiChiara RicciPiercarlo Sarzi-PuttiniMaurizio VecchiGiovanni Maconi

Published in: Journal of gastroenterology and hepatology (2021)

Compared with the general population, IBD patients on biologic therapy are not exposed to a higher risk of COVID-19. Non-gut selective agents are associated with a lower incidence of symptomatic disease, supporting the decision of maintaining the ongoing treatment.

Keyphrases

coronavirus disease
sars cov
rheumatoid arthritis
patients with inflammatory bowel disease
end stage renal disease
newly diagnosed
risk factors
ejection fraction
chronic kidney disease
respiratory syndrome coronavirus
bone marrow
cell therapy